HAVCR2 and ganglioneuroma: Treatment of gal-9 reduced the proportion of CD4+Tim-3+T cells in the spleen and kidneys, and transferred Th1 to Th2, thereby reducing the immune response in anti-GBM GN (Zhang et al., 2014).